Skip to main content
    C

    Caris Life Sciences, Inc. Common Stock (CAI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.00
    -2.04 (-8.85%)

    Market Cap: $6.61B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Caris Life Sciences, Inc. Common Stock (CAI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Caris Life Sciences, Inc. Common Stock reported revenue of $812.03M for the fiscal year ended Dec 31, 2025, up 97.0% from the year before. That year, net income was -$68.09M with a net margin of -8.4%, operating cash flow was $83.16M and free cash flow was $66.89M. The quarter ended Sep 30, 2026 had revenue of $275.36M and net income of $15.25M.

    Revenue and Margins

    The operating margin was 5.6% in the fiscal year ended Dec 2025. Over the 10 years to Dec 2025, revenue grew from $249.67M, a compound annual rate of 12.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$812.03M+97.0%66.4%5.6%-8.4%
    Dec 2024$412.26M+34.7%43.4%-62.4%-68.4%
    Dec 2023$306.13M+18.4%29.2%-104.4%-111.5%
    Dec 2022$258.49MN/A31.0%-122.2%-124.1%
    Dec 2020$294.01M-29.4%62.6%47.3%9.4%
    Dec 2019$416.54M-3.6%48.1%31.3%7.4%
    Dec 2018$432.10M+24.0%49.4%34.4%18.2%
    Dec 2017$348.39M+18.4%48.6%30.3%20.7%
    Dec 2016$294.35M+17.9%46.7%22.4%2.0%
    Dec 2015$249.67MN/A50.4%27.3%10.7%
    Annual, fiscal years ended Dec 2015 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income fell 37.3% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Revenue$812.03M$412.26M$306.13M$258.49M$294.01M$416.54M$432.10M$348.39M$294.35M$249.67M
    Cost of revenue$272.87M$233.48M$216.82M$178.46M$109.86M$216.03M$218.47M$179.11M$156.86M$123.76M
    Gross profit$539.17M$178.78M$89.31M$80.02M$184.16M$200.51M$213.63M$169.29M$137.50M$125.91M
    Research and development$101.58M$113.92M$116.88M$101.27M$0$0$0$0$0$0
    Operating income$45.11M-$257.12M-$319.55M-$315.76M$139.09M$130.28M$148.78M$105.67M$65.96M$68.09M
    Net income-$68.09M-$281.89M-$341.42M-$320.83M$27.73M$31.01M$78.60M$72.06M$6.00M$26.84M
    EBITDAN/A-$183.02M-$266.68M-$245.89M$254.46M$248.30M$283.31M$223.51M$159.27M$181.36M
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Sep 2024Jun 2024Mar 2024Sep 2021Jun 2021
    Revenue$275.36M$263.71M$216.17M$292.89M$216.83M$181.40M$120.92M$101.62M$100.05M$80.68M$100.83M$85.69M
    Gross profit$182.28M$179.60M$141.35M$220.91M$147.51M$113.69M$57.06M$44.41M$37.55M$26.11M$54.09M$42.87M
    Operating income$19.32M$26.93M$5.28M$88.41M$32.64M-$17.99M-$57.95M-$60.84M-$67.01M-$92.22M$66.44M$50.84M
    Net income$15.25M-$637.00K-$510.00K$81.96M$24.32M-$71.79M-$102.58M-$67.73M-$66.19M-$111.03M$51.16M$37.94M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $378.99M by $418.81M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$1.13B$343.73M$412.90M$717.42M$2.61B$2.90B$3.01B$2.43B$2.06B$1.99B
    Current assets$997.80M$215.73M$242.61M$516.04M$214.66M$499.13M$220.02M$140.34M$135.15M$144.11M
    Cash and equivalents$797.80M$65.44M$56.40M$107.19M$53.55M$46.46M$45.31M$35.42M$46.13M$52.55M
    Total liabilities$548.36M$620.92M$2.56B$2.42B$1.91B$2.21B$2.31B$1.87B$1.60B$1.53B
    Short-term debt$169.00K$60.09M$6.75M$57.09M$183.45M$218.09M$311.38M$132.05M$95.53M$172.42M
    Long-term debt$378.82M$319.44M$166.11M$169.57MN/AN/AN/AN/AN/AN/A
    Shareholder equity$577.31M-$2.50B-$2.14B-$1.70B$702.24M$693.24M$701.13M$563.85M$457.50M$460.34M
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Jun 2024Mar 2024Dec 2023Dec 2022
    Total assets$1.26B$1.23B$1.16B$1.13B$984.57M$955.06M$291.58MN/AN/AN/A$412.90M$717.42M
    Total liabilities$616.14M$637.89M$568.90M$548.36M$506.21M$502.15M$2.89BN/AN/AN/A$2.56B$2.42B
    Cash and equivalentsN/A$690.91M$821.15M$797.80M$754.74M$718.93M$31.20MN/AN/AN/A$56.40M$107.19M
    Shareholder equity$639.48M$591.73M$593.49M$577.31M$478.36M$452.90M-$2.60BN/AN/AN/A-$2.14B-$1.70B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 80.4% of operating cash flow. Share repurchases came to 11.7% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow$83.16M-$245.20M-$276.10M-$285.71M$277.02M$254.00M$179.77M$155.19M$129.26M$147.37M
    Capital expenditures$16.26M$8.44M$22.32M$42.26M$219.45M$319.14M$812.84M$502.18M$251.25M$389.41M
    Free cash flow$66.89M-$253.64M-$298.42M-$327.96M$57.57M-$65.14M-$633.07M-$346.98M-$121.99M-$242.04M
    Dividends paidN/AN/AN/AN/A$17.71M$8.83M$3.26MN/AN/AN/A
    Share repurchases$7.82M$1.06M$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$16.26M$52.93M$214.77M-$282.99M-$33.97M-$271.87M-$663.34M-$411.75M-$181.60M-$305.25M
    Financing cash flow$664.99M$200.29M$10.13M$10.45M-$249.88M-$108.48M$512.35M$245.63M$46.60M$156.54M
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    Operating cash flow-$22.25M$28.48M$32.88M$44.78M$62.42M$7.29M-$31.34M-$38.92M-$69.43M-$62.93M-$73.92M
    Capital expenditures$17.47M$22.07M$10.34M$5.09M$7.09M$1.39M$2.69M$2.29M$1.83M$2.59M$1.74M
    Free cash flow-$39.72M$6.40M$22.53M$39.69M$55.33M$5.90M-$34.03M-$41.21M-$71.25M-$65.51M-$75.66M
    Last 11 quarters

    Frequently Asked Questions About CAI

    What is Caris Life Sciences, Inc. Common Stock's annual revenue?

    Caris Life Sciences, Inc. Common Stock reported revenue of $812.03M for the fiscal year ended Dec 31, 2025.

    How fast is Caris Life Sciences, Inc. Common Stock's revenue growing?

    Revenue was up 97.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 46.5%.

    Is Caris Life Sciences, Inc. Common Stock profitable?

    No. Caris Life Sciences, Inc. Common Stock reported net income of -$68.09M for the fiscal year ended Dec 31, 2025, with a net margin of -8.4%.

    How much free cash flow does CAI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $83.16M minus capital expenditures of $16.26M produced free cash flow of $66.89M.

    How much debt does Caris Life Sciences, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $378.82M, short-term debt of $169.00K and cash and equivalents of $797.80M.